Q1 FY27 results: PAT up 25%, revenue up 16% YoY; Lannett deal closed

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹1615.00

prior close

₹1625.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.4%-1.2% vs market

Pharmaceuticals peers, median of 167sector-0.2%-1.5% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Midcap 150 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-1.2

15m

-1.0

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6-0.4-1.2-0.2-1.5

Next day

+2.7-0.2+2.8+0.3+2.3

+2.0+0.3+1.8+0.6+1.4

+2.4+0.2+2.2+0.6+1.8

+3.0+0.5+2.5+0.5+2.5

+3.0+0.6+2.4+0.9+2.1

+0.8+0.2+0.5-0.2+1.0

15d

+0.5+0.4+0.1-0.2+0.7

+2.7-1.5+4.1+2.3+0.4

+4.4-6.1+10.5+2.4+2.0

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated revenue up 16% YoY at Rs 91,503 million; PAT up 25% at Rs 10,320 million, EPS Rs 17.86. Standalone PAT up 32% at Rs 7,372 million. Completed Lannett acquisition for USD 247 million with Rs 402 million in exceptional costs. Approved merger of two Eugia step-down subs into Eugia Pharma Specialities. Buyback of Rs 8,065 million completed earlier. Auditor gave clean unmodified review opinion.

Likely market impact

Strong Q1 with double-digit profit growth, US expansion via Lannett, and subsidiary consolidation support earnings outlook.